A new partnership between MGI Tech and Queensland's National Centre for Spatial Tissue and AI Research is bringing integrated multi-omics infrastructure to Australia, enabling researchers to match individual cancer patients with therapies most likely to work for them. The collaboration signals a broader shift in oncology: after decades of developing more cancer drugs, the real challenge now is figuring out which patients should receive which treatments.

Why Matching Patients to Drugs Matters More Than Ever?

Over 200 targeted cancer drugs have been approved by major regulators like the FDA, yet many patients still don't benefit from them. The bottleneck isn't drug discovery anymore; it's understanding which patients have the specific biological markers that make a drug effective for their tumor. This is the essence of precision medicine.

Dr. David Parkinson, who oversaw the clinical development of Gleevec, one of oncology's landmark targeted therapies, explained the evolution: "Advances in our understanding of cancer biology, together with technological improvements that enable us to target historically challenging pathways, continue to expand our ability to develop more precise therapeutics." He added that "the ever-growing ability to characterize the biology of an individual patient's tumor in greater detail at a specific point in time and correlate those findings with targeted treatment approaches" is now central to drug development success.

What Technologies Are Now Available in Queensland?

Through the memorandum of understanding signed on August 4, 2026, QIMR Berghofer's National Centre for Spatial Tissue and AI Research (NCSTAR) gained access to MGI's integrated DCSP framework, which stands for DNA, Cell, Spatial omics, and Proteomics. This suite of tools allows researchers to examine tumors at multiple biological levels simultaneously.

• DNBSEQ Sequencing: Provides DNA genomics with industry-leading accuracy and low amplification error rates, creating a reliable foundation for identifying immune-relevant genetic variants in cancer cells.
• Elab C-series Single-Cell Platform: Uses droplet-based partitioning to analyze individual cells, capturing gene expression and immune receptor profiles with high accuracy and low duplicate rates.
• Stereo-seq Spatial Transcriptomics: Delivers nanoscale-resolution mapping of gene expression across tissue sections, working on both fresh-frozen and preserved samples without requiring pre-designed gene panels.
• VisiOmics Multiplex Immunofluorescence: Enables automated analysis of over 100 protein markers simultaneously on a single tissue section, allowing researchers to visualize how proteins and RNA interact within tumors.

The advantage of having these tools on campus at QIMR Berghofer is immediate and practical. Researchers can test new spatial biology platforms against their own patient samples and research questions before committing to large-scale studies, accelerating the validation process.

How Large-Scale Genomic Data Is Transforming Cancer Research

One of the most significant developments enabling precision oncology is the availability of large, clinically annotated genomic datasets. The American Association for Cancer Research's Project GENIE, for example, links genomic sequencing data with clinical outcomes across hundreds of thousands of patients, providing researchers with the statistical power to identify meaningful biological patterns.

Dr. Parkinson emphasized the impact: "Large-scale genomic sequencing efforts in clinically annotated patient populations, supported by new computational technologies and AI, promise a more efficient road towards developing effective therapies in the future. It is an extremely exciting time." This combination of massive datasets and artificial intelligence allows researchers to spot which tumor characteristics predict treatment response, something that would be impossible to detect manually.

Dr. Parkinson

The challenge, however, remains substantial. As Parkinson noted, "Biological understanding and technological advances increasingly allow us to target nearly any relevant pathway therapeutically. The challenge of identifying the relevance of a given target within a particular patient, or even a specific subgroup of patients, remains significant. Establishing the value of that therapeutic approach convincingly in real-world patient populations is daunting".

As Parkinson

Steps to Translate Spatial Biology Into Clinical Practice

The NCSTAR and MGI partnership demonstrates how research institutions can move spatial omics from the laboratory into real clinical applications. Here's how this collaboration is structured to accelerate that translation:

• On-Campus Technology Access: By operating the MGI Australia and New Zealand Customer Experience Centre directly at QIMR Berghofer since 2021, researchers can immediately test new spatial platforms against their own samples and workflows, eliminating delays in technology evaluation.
• Technical Training and Knowledge Exchange: MGI's local team provides hands-on training to NCSTAR researchers in spatial omics data generation and analysis, deepening their expertise and enabling them to teach other Queensland research groups.
• Pipeline for Joint Projects: The MOU creates a formal pathway for collaborative research, publications, and grant applications, ensuring that validated technologies move directly into active studies rather than remaining as proof-of-concept demonstrations.
• Broader Community Benefit: NCSTAR intends to share its spatial omics expertise with collaborating research groups across Queensland, multiplying the impact of the partnership beyond a single institution.

Associate Professor Quan Nguyen, Director of NCSTAR, stated: "Having MGI's technology and technical team on our own campus means we don't have to wait to find out whether a new spatial platform works for our samples and our research questions. We can test it and refine it here, and bring it into our studies with confidence. Together with NCSTAR's strengths in spatial tissue analysis, imaging, bioinformatics and AI-enabled research, this MOU helps establish what we believe is one of the world's most comprehensive spatial multi-omics technology capabilities in one building".

Quan Nguyen, Director of NCSTAR

What Does This Mean for Cancer Patients?

The ultimate goal of precision oncology is straightforward: give each patient the drug most likely to work for their specific tumor, while sparing them from ineffective treatments and their side effects. The partnership between NCSTAR and MGI represents infrastructure investment in that direction.

Dr. Bicheng Yang, Director of MGI Australia and New Zealand, explained the company's philosophy: "Since establishing our presence at QIMR Berghofer in 2016, our focus has been on empowering the local research ecosystem rather than simply showcasing hardware. Working with NCSTAR lets us put that infrastructure directly to work for one of the world's leading spatial tissue and AI research programs, and support the validation work that helps new technology move from the lab bench into everyday research that generates real clinical insight".

Bicheng Yang, Director of MGI Australia and New Zealand

MGI's DCSP Lab Initiative, which was upgraded in 2026 to include full-stack proteomics, has already supported the establishment of more than 49 similar research centers worldwide as of December 31, 2025. The Queensland partnership joins a growing global network of institutions using integrated multi-omics and AI to accelerate the translation of genomic discoveries into clinical benefits.